Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Deutsche Bank cuts Harmony Biosciences stock rating on patent risk
Deutsche Bank has downgraded Harmony Biosciences (NASDAQ: HRMY) to Hold from Buy and lowered its price target due to increased patent risk for its lead drug, Wakix. A recent bench trial indicated a negative outcome for Harmony Biosciences against a generics manufacturer, potentially accelerating Wakix’s loss of exclusivity. Despite the legal uncertainty, the stock appears undervalued according to InvestingPro analysis, even as shares declined following the trial’s conclusion.